Amicus to abandon wound treatment after it fails late-stage trial

(Reuters) - U.S. drug developer Amicus Therapeutics Inc said on Wednesday it will not invest in any more clinical trials of its drug to heal wounds, after the experimental treatment failed to meet the main goals of a late-stage trial.